Pharmacological and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease Pathophysiology
Date & Time
Friday, November 3rd / 9:45 AM
Authors and Affiliations
1-Department of Cell Biology, Duke University Medical Center, Durham, NC 27710.
2-Department of Biology, Duke Trinity College of Arts and Sciences, Durham, NC 27710.
3-National Center for Advancing Translational Sciences (NCATS), NIH Division of Preclinical Innovation, Rockville, MD 20892.
About Joshua Gross
"I am a neuropharmacologist interested in exploiting GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases, including obesity, eating disorders, and diabetes.
I received my PhD in Cellular & Integrative Physiology from West Virginia University under the mentorship of Drs. David Siderovski and Vincent Setola (2014-2019). I am currently completing my postdoctoral research in the laboratory of the late Dr. Marc Caron (2019-2023) and subsequently, will begin my independent research career as a tenure-track Assistant Professor at Penn State University (University Park) in August 2023.
My broad research interest is to better understand the underlying mechanisms of food reward and its downstream dysregulation of metabolic function, particularly in response to obesogenic 'Western' diets (aka, ultra-processed food). With my expertise in reward behavior, neurophysiology, GPCR signaling, and preclinical drug development, my lab will strive to develop novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases. "